Welcome to CDC Stacks | Prevention of Pneumococcal Disease Among Infants and Children - Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine - Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2011; 59 (No. RR-11): 1-18. - 7454 | Guidelines and Recommendations
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Prevention of Pneumococcal Disease Among Infants and Children - Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine - Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2011; 59 (No. RR-11): 1-18.
  • Published Date:
    March 12, 2010
  • Status:
    current
  • Source:
    MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control. 2010; 59(RR-11):1-18.
  • Language:
    English
Filetype[HTML - ]


This is an HTML document so it cannot be previewed.
To open, click the "View" button.
Details:
  • Corporate Authors:
    United States. Advisory Committee on Immunization Practices.
  • Description:
    On February 24, 2010, a 13-valent pneumococcal polysaccharide-protein conjugate vaccine (PCV13 [Prevnar 13, Wyeth Pharmaceuticals Inc., marketed by Pfizer Inc.]) was licensed by the Food and Drug Administration (FDA) for prevention of invasive pneumococcal disease (IPD) caused among infants and young children by the 13 pneumococcal serotypes covered by the vaccine and for prevention of otitis media caused by serotypes also covered by the 7-valent pneumococcal conjugate vaccine formulation (PCV7 [Prevnar, Wyeth]). PCV13 contains the seven serotypes included in PCV7 (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and six additional serotypes (serotypes 1, 3, 5, 6A, 7F, and 19A). PCV13 is approved for use among children aged 6 weeks-71 months and supersedes PCV7, which was licensed by FDA in 2000. This report summarizes recommendations approved by the Advisory Committee on Immunization Practices (ACIP) on February 24, 2010, for the use of PCV13 to prevent pneumococcal disease in infants and young children aged <6 years.

  • Supporting Files:
    No Additional Files
  1. Source:
    Description:
    Status:
    File Type:
  2. Source:
    Description:
    Status:
    File Type:
  3. Source:
    Description:
    Status:
    File Type:
  4. Corporate Author:
    Published:
    Source:
    Description:
    Status:
    File Type:
  5. Source:
    Status:
    File Type:
  6. Source:
    Description:
    Status:
    File Type:
  7. Corporate Author:
    Source:
    Description:
    Status:
    File Type:
  8. Source:
    Description:
    Status:
    File Type:
You May Also Like: